Medical News / ERS 2020: Monotherapy LAMA is Over-Used, Linked to Asthma Exacerbation Risk

Long-acting muscarinic antagonists (LAMA) are frequently prescribed out of step with guidance for treating patients with asthma, according to a new study. In new data presented virtually during the European Respiratory Society (ERS) 2020 Congress this week, a team of investigators from the Netherlands and Belgium showed monotherapy LAMA is prevalent among nearly 40% of observed users with asthma—despite its indication being for add-on use. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
Every other year, the American Academy of Ophthalmology (AAO) hosts a Uveitis Subspeciality Day as part ... read more
During the American Academy of Ophthalmology (AAO) 2020 Virtual Conference, new technologies and innovations were a ... read more
In new data presented at the American College of Ophthalmology (AAO) 2020 Virtual Conference, investigators examined ... read more
According to a study presented at the American College of Ophthalmology (AAO) 2020 Virtual Conference, intravitreal ... read more